Literature DB >> 1184741

Heme synthetase deficiency in human protoporphyria. Demonstration of the defect in liver and cultured skin fibroblasts.

H L Bonkowsky, J R Bloomer, P S Ebert, M J Mahoney.   

Abstract

The final step in heme biosynthesis is chelation of porphyrin with Fe++ catalyzed by the mitochondrial enzyme heme synthetase. We have employed a sensitive radiochemical assay for this enzyme, using 59Fe and deuteroporphyrin or protoporphyrin as substrates. In this method iron is maintained in the ferrous state, oxygen is excluded from the incubation system, and labeled heme product is extracted into ethyl acetate. This assay has been used to measure the activity of heme synthetase in homogenates of liver, obtained by needle biopsy, and in sonicates of human skin fibroblasts, cultured in vitro. In addition, activity of the first enzyme of the heme synthetic pathway, delta-aminolevulinic acid synthetase, has been measured in fibroblast lysates. Lysates of fibroblasts from eight patients with protoporphyria had activities of delta-aminolevulinic acid synthetase which did not differ significantly from those of eight normal fibroblast lines, whereas activity of heme synthetase, with either deuteroporphyrin or protoporphyrin as substrate, was markedly decreased in sonicates of skin fibroblasts from these patients, the mean being 8% of control with deuteroporphyrin and 14% with protoporphyrin as substrate. In homogenates of liver from five patients with protoporphyria, activity of heme synthetase was also significantly less than that found in six patients without prophyria, the mean being 13% of control with protoporphyrin as substrate. These results provide evidence that decreased activity of heme synthetase is the basic defect in the heme synthetic pathway in protoporphyria. This deficiency is probably responsible for protoporphyrin accumulation and hence the biochemical and clinical features observed in protoporphyria.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1184741      PMCID: PMC301976          DOI: 10.1172/JCI108189

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  35 in total

1.  Porphyrin synthesis and mitochondrial respiration in acute intermittent porphyria: studies using cultured human fibroblasts.

Authors:  H L Bonkowsky; D P Tschudy; E C Weinbach; P S Ebert; J M Doherty
Journal:  J Lab Clin Med       Date:  1975-01

2.  Microsomal heme oxygenase. Characterization of the enzyme.

Authors:  R Tenhunen; H S Marver; R Schmid
Journal:  J Biol Chem       Date:  1969-12-10       Impact factor: 5.157

3.  Hepatic delta-aminolaevulinic acid synthetase in an attack of hereditary coproporphyria and during remission.

Authors:  N McIntyre; A J Pearson; D J Allan; S Craske; G M West; M R Moore; A D Beattie; J Paxton; A Goldberg
Journal:  Lancet       Date:  1971-03-20       Impact factor: 79.321

4.  Heme formation from Fe(II) and porphyrin in the absence of ferrochelatase activity.

Authors:  R J Kassner; H Walchak
Journal:  Biochim Biophys Acta       Date:  1973-04-28

5.  Birefringence of hepatic pigment deposits in erythropoietic protoporphyria. Specificity of polarization microscopy in the identification of hepatic protoporphyrin deposits.

Authors:  G Klatskin; J R Bloomer
Journal:  Gastroenterology       Date:  1974-08       Impact factor: 22.682

6.  Erythropoietic protoporphyria with features of a sideroblastic anaemia terminating in liver failure.

Authors:  A J Scott; A J Ansford; B H Webster; H C Stringer
Journal:  Am J Med       Date:  1973-02       Impact factor: 4.965

7.  The serum porphobilinogen and hepatic porphobilinogen deaminase in normal and porphyric individuals.

Authors:  K Miyagi; R Cardinal; I Bossenmaier; C J Watson
Journal:  J Lab Clin Med       Date:  1971-11

8.  Chloramphenicol-induced erythroid suppression and bone marrow ferrochelatase activity in dogs.

Authors:  D R Manyan; G K Arimura; A A Yunis
Journal:  J Lab Clin Med       Date:  1972-01

9.  A microassay for uroporphyrinogen I synthase, one of three abnormal enzyme activities in acute intermittent porphyria, and its application to the study of the genetics of this disease.

Authors:  S Sassa; S Granick; D R Bickers; H L Bradlow; A Kappas
Journal:  Proc Natl Acad Sci U S A       Date:  1974-03       Impact factor: 11.205

10.  Heme biosynthesis in intermittent acute prophyria: decreased hepatic conversion of porphobilinogen to porphyrins and increased delta aminolevulinic acid synthetase activity.

Authors:  L J Strand; B F Felsher; A G Redeker; H S Marver
Journal:  Proc Natl Acad Sci U S A       Date:  1970-11       Impact factor: 11.205

View more
  47 in total

1.  The diagnosis and management of erythropoietic protoporphyria.

Authors:  Manish Thapar; Herbert L Bonkovsky
Journal:  Gastroenterol Hepatol (N Y)       Date:  2008-08

2.  Strong correlation of ferrochelatase enzymatic activity with Mitoferrin-1 mRNA in lymphoblasts of patients with protoporphyria.

Authors:  John Phillips; Collin Farrell; Yongming Wang; Ashwani K Singal; Karl Anderson; Manisha Balwani; Montgomery Bissell; Herbert Bonkovsky; Toni Seay; Barry Paw; Robert Desnick; Joseph Bloomer
Journal:  Mol Genet Metab       Date:  2018-10-22       Impact factor: 4.797

Review 3.  Liver disease in erythropoietic protoporphyria: insights and implications for management.

Authors:  A V Anstey; R J Hift
Journal:  Postgrad Med J       Date:  2007-12       Impact factor: 2.401

Review 4.  Liver disease in erythropoietic protoporphyria: insights and implications for management.

Authors:  A V Anstey; R J Hift
Journal:  Gut       Date:  2007-03-14       Impact factor: 23.059

5.  Systematic analysis of molecular defects in the ferrochelatase gene from patients with erythropoietic protoporphyria.

Authors:  U B Rüfenacht; L Gouya; X Schneider-Yin; H Puy; B W Schäfer; R Aquaron; Y Nordmann; E I Minder; J C Deybach
Journal:  Am J Hum Genet       Date:  1998-06       Impact factor: 11.025

6.  Molecular defects in ferrochelatase in patients with protoporphyria requiring liver transplantation.

Authors:  J Bloomer; C Bruzzone; L Zhu; Y Scarlett; S Magness; D Brenner
Journal:  J Clin Invest       Date:  1998-07-01       Impact factor: 14.808

7.  The molecular defect of ferrochelatase in a patient with erythropoietic protoporphyria.

Authors:  Y Nakahashi; H Fujita; S Taketani; N Ishida; A Kappas; S Sassa
Journal:  Proc Natl Acad Sci U S A       Date:  1992-01-01       Impact factor: 11.205

Review 8.  The ferrochelatase gene structure and molecular defects associated with erythropoietic protoporphyria.

Authors:  S Taketani; H Fujita
Journal:  J Bioenerg Biomembr       Date:  1995-04       Impact factor: 2.945

9.  Posttranslational stability of the heme biosynthetic enzyme ferrochelatase is dependent on iron availability and intact iron-sulfur cluster assembly machinery.

Authors:  Daniel R Crooks; Manik C Ghosh; Ronald G Haller; Wing-Hang Tong; Tracey A Rouault
Journal:  Blood       Date:  2009-11-25       Impact factor: 22.113

10.  An autopsy case of acute porphyria with a decrease of both uroporphyrinogen I synthetase and ferrochelatase activities.

Authors:  M Yamada; M Kondo; M Tanaka; R Okeda; S Hatakeyama; T Fukui; H Tsukagoshi
Journal:  Acta Neuropathol       Date:  1984       Impact factor: 17.088

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.